BACKGROUND: Serologic testing for herpes simplex virus type-2 (HSV-2) is being implemented in sexually transmitted disease (STD) clinics. GOAL: To determine the performance characteristics of two HSV-2 type-specific serologic assays in a public health laboratory. STUDY DESIGN: Sera stored from a cross-sectional study were tested with the Meridian Diagnostics and Focus Technologies HSV-2 ELISA tests and a type-specific strip immunoblot assay (Chiron Corp.) was used as the reference standard. RESULTS: Prevalence of HSV-2 infection in this sample was 44%. Compared to the reference standard, the sensitivity of the Meridian Diagnostics HSV-2 test was 95.5% (95% CI 83.3, 99.2) and specificity was 98.2% (95% CI 89.0, 99.9). The Focus Technologies test yielded 97.7% (95% CI 86.5, 99.9) sensitivity and 94.5% (95% CI 83.9, 98.6) specificity. CONCLUSIONS: The performance of these HSV-2 type-specific serologic assays was adequate to support their use in high prevalence populations, such as STD clinic patients.
BACKGROUND: Serologic testing for herpes simplex virus type-2 (HSV-2) is being implemented in sexually transmitted disease (STD) clinics. GOAL: To determine the performance characteristics of two HSV-2 type-specific serologic assays in a public health laboratory. STUDY DESIGN: Sera stored from a cross-sectional study were tested with the Meridian Diagnostics and Focus Technologies HSV-2 ELISA tests and a type-specific strip immunoblot assay (Chiron Corp.) was used as the reference standard. RESULTS: Prevalence of HSV-2 infection in this sample was 44%. Compared to the reference standard, the sensitivity of the Meridian Diagnostics HSV-2 test was 95.5% (95% CI 83.3, 99.2) and specificity was 98.2% (95% CI 89.0, 99.9). The Focus Technologies test yielded 97.7% (95% CI 86.5, 99.9) sensitivity and 94.5% (95% CI 83.9, 98.6) specificity. CONCLUSIONS: The performance of these HSV-2 type-specific serologic assays was adequate to support their use in high prevalence populations, such as STD clinic patients.
Authors: Hayley D Mark; Joy P Nanda; Jessica Roberts; Anne Rompalo; Johan H Melendez; Jonathan Zenilman Journal: Sex Transm Dis Date: 2007-09 Impact factor: 2.830
Authors: Hayley Mark; Joy P Nanda; Alain Joffe; Jessica Roberts; Anne Rompalo; Johan Melendez; Jonathan Zenilman Journal: J Am Coll Health Date: 2008 Nov-Dec
Authors: Nicole Brenner; Alexander J Mentzer; Julia Butt; Angelika Michel; Kristina Prager; Johannes Brozy; Benedikt Weißbrich; Allison E Aiello; Helen C S Meier; Judy Breuer; Rachael Almond; Naomi Allen; Michael Pawlita; Tim Waterboer Journal: PLoS One Date: 2018-12-27 Impact factor: 3.240